Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: A review of the literature

Diabetes Research and Clinical Practice

Volumn 109, Issue 2, 2015, Pages 215-225

  Alleman, Cathelijne J M ^a   Westerhout, Kirsten Y ^a   Hensen, Marja ^a   Chambers, Colette ^b   Stoker, Malcolm ^c   Long, Stephen ^d   van Nooten, Floortje E ^c  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^c Astellas Pharma Global Development   (Netherlands)

^d SYNEOS HEALTH   (United States)

Author keywords

Burden; Epidemiology; Europe; Literature review; Painful diabetic neuropathy; Quality of life

Indexed keywords

ANXIETY; DEPRESSION; DIABETIC NEUROPATHY; DISEASE SEVERITY; EUROPE; HEALTH CARE COST; HUMAN; HUMANISM; INCIDENCE; NEUROPATHIC PAIN; PAIN INTENSITY; PREVALENCE; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SLEEP; SYSTEMATIC REVIEW; COST OF ILLNESS; DIABETIC NEUROPATHIES; ECONOMICS; PSYCHOLOGY;

COST OF ILLNESS; DIABETIC NEUROPATHIES; EUROPE; HEALTH CARE COSTS; HUMANS; PREVALENCE; QUALITY OF LIFE;

EID: 84937976565     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.04.031     Document Type: Review

References (58)

1. Tesfaye S., Selvarajah D. The Eurodiab study: what has this taught us about diabetic peripheral neuropathy. Curr Diabetes Rep 2009, 9(6):432-434.
2. Boulton A.J.M., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R., et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28(4):956-962. [accessed 12.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/15793206〉.
3. Vinik A.I., Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007, 115(3):387-397. [accessed 12.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/17242296〉.
4. National Institute for Health and Care Excellence (NICE). NICE clinical guideline 173. Neuropathic pain-pharmacological management. The pharmacological management of neuropathic pain in adults in non-speicalist settings. November 2013.
5. Tesfaye S. Advances in the management of diabetic peripheral neuropathy. Curr Opin Support Palliat Care 2009, 3(2):136-143. [accessed 12.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/19421063〉.
6. Jensen M.P., Chodroff M.J., Dworkin R.H. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007, 68(15):1178-1182. [accessed 12.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/17420400〉.
7. O'Connor A.B. Neuropathic pain. Quality-of-life impact, costs and cost effectiveness of therapy. PharmacoEconomics 2009, 27(2):95-112.
8. Deshpande M.A., Holden R.R., Gilron I. The impact of therapy on quality of life and mood in neuropathic pain: what is the effect of pain reduction. Anesth Analg 2006, 102(5):1473-1479. [accessed 12.03.13]. 〈http://www., ncbi., nlm., nih., gov/pubmed/16632829〉.
9. Attal N., Cruccu G., Baron R., Haanpää M., Hansson P., Jensen T.S., et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol: Off J Eur Fed Neurol Soc 2010, 17(9):1113-1188. [accessed 19.06.11]. 〈http://www.ncbi.nlm.nih.gov/pubmed/20402746〉.
10. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977-986. The Diabetes Control and Complications Trial Research Group, [accessed 22.07.14]. 〈http://www.ncbi.nlm.nih.gov/pubmed/8366922〉.
11. Kerr L. Polypharmacy in diabetes and solutions for greater adherence. Pract Diabetes 2009, 26(7):289-291.
12. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J (Clin Res ed) 2009, 339:b2535. [accessed 18.03.13]. 〈http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2714657&tool=pmcentrez&rendertype=Abstract〉.
13. XE. XE Currency Converter, 〈http://www.xe.com/〉 [accessed 26.03.13].
14. Abbott C.A., Malik R.A., van Ross E.R.E., Kulkarni J., Boulton A.J.M. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the UK. Diabetes Care 2011, 34(10):2220-2224. [accessed 7.03.13]. 〈http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3177727&tool=pmcentrez&rendertype=Abstract〉.
15. Bouhassira D., Hartemann A., Letanoux M. Prevalence of neuropathic pain in diabetic patients: a French cross-sectional study. Eur J Pain Suppl 2011, 5(1):161. [accessed 7.03.13]. 〈http://linkinghub.elsevier.com/retrieve/pii/S1754320711705545〉.
16. Daousi C., MacFarlane I.A., Woodward A., Nurmikko T.J., Bundred P.E., Benbow S.J. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med: J Br Diabet Assoc 2004, 21(9):976-982. [accessed 7.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/15317601〉.
17. Dieleman J.P., Kerklaan J., Huygen F.J.P.M., Bouma P.A D., Sturkenboom M.C.J.M. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008, 137(3):681-688. [accessed 7.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/18439759〉.
18. Hall G.C., Carroll D., McQuay H.J. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Fam Pract 2008, 9:26. [accessed 30.07.12]. 〈http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2413228&tool=pmcentrez&rendertype=Abstract〉.
19. La Cesa S., Truini A., Leonetti F., Jann S., Franceschini L.D.T., Zanette G., et al. Prevalence of peripheral neuropathies and neuropathic pain in patients with diabetes. Preliminary results of an Italian mulitcentre study. Eur J Neurol 2011, 18(Suppl. 2):191.
20. Rubino A., Rousculp M.D., Davis K., Wang J., Bastyr E.J., Tesfaye S. Diagnosis of diabetic peripheral neuropathy among patients with type 1 and type 2 diabetes in France, Italy, Spain, and the United Kingdom. Prim Care Diabetes 2007, 1(3):129-134. [accessed 07.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/18632033〉.
21. Truini A., Leonette F.J., De Toni Franceshini L., Zanette G., Praitano M., Schenone A., et al. Prevalence of peripheral neuropathies and neuropathic pain in patients with diabetes. Preliminary results of an Italian multicenter study. J Peripher Nerv Syst: JPNS 2011, 16:S36-S37. [Suppl.].
22. Van Acker K., Bouhassira D., De Bacquer D., Weiss S., Matthys K., Raemen H., et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009, 35(3):206-213. [accessed 07.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/19297223〉.
23. Van Kollenburg E.G.P., Lavrijsen J.C.M., Verhagen S.C., Zuidema S.U., Schalkwijk A., Vissers K.C.P. Prevalence, causes, and treatment of neuropathic pain in Dutch nursing home residents: a retrospective chart review. J Am Geriatr Soc 2012, 60(8):1418-1425. [accessed 07.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/22788732〉.
24. Wu E.Q., Borton J., Said G., Le T.K., Monz B., Rosilio M., et al. Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France. Curr Med Res Opin 2007, 23(9):2035-2042. [accessed 07.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/17637204〉.
25. Ziegler D., Rathmann W., Dickhaus T., Meisinger C., Mielck A. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA augsburg surveys S2 and S3. Pain Med (Malden, Mass) 2009, 10(2):393-400. [accessed 07.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/19207236〉.
26. Ziegler D., Rathmann W., Meisinger C., Dickhaus T., Mielck A. Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA myocardial infarction registry. Eur J Pain (London, England) 2009, 13(6):582-587. [accessed 07.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/18782673〉.
27. Cash T., Selvaraja D., Roddick A., Thomas L., Gandhi R., Tesfaye S. A population-based study of the relationship between neuropathic pain severity and important patient-related health outcomes in diabetic neuropathy: time to revaluate current clinical practice. Diabet Med: J Br Diabet Assoc 2012, 29(Suppl. 1):14.
28. Currie C.J., Poole C.D., Woehl A., Morgan C.L., Cawley S., Rousculp M.D., et al. The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 2006, 49(10):2272-2280. [accessed 19.10.11]. 〈http://www.ncbi.nlm.nih.gov/pubmed/16944094〉.
29. D'Amato C., Morganti R., Di Gennaro F., Greco C., Cacciotti L., Rotella S., et al. Neuropathic pain impact on sleep and circadian rhythm of blood pressure in painful diabetic polyneuropathy. J Peripher Nerv Syst: JPNS 2012, 17:S19. [Suppl.].
30. Schneider E., Birklein F., Wilhelm S., Schacht A., Ziegler D. Diabetic peripheral neuropathic pain: Patient characteristics, diagnoses and treatment in clinical practice. Schmerz 2011, 97. [Suppl.].
31. Schneider E., Ziegler D., Wilhelm S., Schacht A., Birklein F. Patient expectations and physicians' judgement in the treatment of diabetic peripheral neuropathic pain. Eur J Pain Suppl 2011, 5(1):55. [accessed 07.03.13]. 〈http://linkinghub.elsevier.com/retrieve/pii/S1754320711701845〉.
32. Spallone V., Morganti R., D'Amato C., Greco C., Di Gennaro F., Cacciotti L., et al. Nondipping is a novel associated disorder of painful diabetic polyneuropathy. Diabetologica 2012, 55(Suppl. 1):S480.
33. Tahrani A., Ali A., Begu S., Dubb K., Mughal S., Piya M., et al. Obstructive sleep apnoea is independently associated with peripheral neuropathy in patients with type 2 diabetes. Diabetes 2011, 60(Suppl. 1):SA107.
34. Taylor-Stokes G., Pike J., Sadosky A., Chandran A., Toelle T. Association of patient-rated severity with other outcomes in patients with painful diabetic peripheral neuropathy in Europe. Pain Pract 2012, 12(Suppl. 1):S108.
35. Thomas L., Selvarajah D., Cash T., Gandhi R., Sankar A., Davies J., et al. A biopsychosocial examination of factors contributing to sleep impairment in painful diabetic neuropathy. Diabetologia 2012, 55(Suppl. 1):S480.
36. Vileikyte L., Peyrot M., Gonzalez J.S., Rubin R.R., Garrow a P., Stickings D., et al. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study. Diabetologia 2009, 52(7):1265-1273. [accessed 07.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/19399473〉.
37. Currie C.J., Poole C.D., Woehl A., Morgan C.L., Cawley S., Rousculp M.D., et al. The financial costs of healthcare treatment for people with type 1 or type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet Med: J Br Diabet Assoc 2007, 24(2):187-194. [accessed 07.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/17257282〉.
38. Sicras-mainar A., Rejas J., Navarro-artieda R., Planas A., Collados C. Cost analysis of adding pregabalin or gabapentin to usual care in the management of community-treated patients with painful diabetes peripheral neuropathy in Spain. Value Health 2012, 15(7):A497. [accessed 07.03.13]. 〈http://linkinghub.elsevier.com/retrieve/pii/S1098301512033803〉.
39. Taylor-Stokes G., Pike J., Sadosky A., Chandran A., Toelle T. Impact of patient-rated severity of painful diabetic peripheral neuropathy on productivity in the European setting. Pain Pract 2012, 12(Suppl. 1):S111-S112.
40. Davies M., Brophy S., Williams R., Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006, 29(7):1518-1522. [accessed 07.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/16801572〉.
41. Hall G.C., Carroll D., Parry D., McQuay H.J. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain 2006, 122(1-2):156-162. [accessed 06.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/16545908〉.
42. Baron R., Tölle T.R., Gockel U., Brosz M., Freynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. Pain 2009, 146(1-2):34-40. [accessed 07.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/19592166〉.
43. De Salas-Cansado M., Pérez C., Saldaña M.T., Navarro A., González-Gómez F.J., Ruiz L., et al. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings. Prim Care Diabetes 2012, 6(4):303-312. [accessed 07.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/22595032〉.
44. Beard S.M., McCrink L., Le T.K., Garcia-Cebrian A., Monz B., Malik R.A. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Curr Med Res Opin 2008, 24(2):385-399. [accessed 13.09.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/18157921〉.
45. Rodríguez M.J., Díaz S., Vera-Llonch M., Dukes E., Rejas J. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin 2007, 23(10):2585-2596. [accessed 19.10.11]. 〈http://www.ncbi.nlm.nih.gov/pubmed/17875242〉.
46. Tölle T., Xu X., Sadosky A.B. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complicat 2006, 20(1):26-33. [accessed 04.08.11]. 〈http://www.ncbi.nlm.nih.gov/pubmed/16389164〉.
47. Baron R., Mayoral V., Leijon G., Binder A., Steigerwald I., Serpell M. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009, 25(7):1663-1676. [accessed 07.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/19485723〉.
48. Hoffman D.L., Sadosky A., Dukes E.M., Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy. Pain 2010, 149(2):194-201. [accessed 01.11.11]. 〈http://www.ncbi.nlm.nih.gov/pubmed/20303665〉.
49. Galer B.S., Sheldon E., Patel N., Codding C., Burch F., Gammaitoni A.R. Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis. Curr Med Res Opin 2004, 20(9):1455-1458. [accessed 16.12.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/15383194〉.
50. Bautista R.E.D., Erwin P.A. Analyzing depression coping strategies of patients with epilepsy: a preliminary study. Seizure: J Br Epilepsy Assoc 2013, 22(9):686-691. [May 24, accessed 01.10.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/23711614〉.
51. Wang J., Wang Y., Wang L.B., Xu H., Zhang X. A comparison of quality of life in adolescents with epilepsy or asthma using the short-form health survey (SF-36). Epilepsy Res 2012, 101(1-2):157-165. [accessed 01.10.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/22512895〉.
52. Kontodimopoulos N., Pappa E., Chadjiapostolou Z., Arvanitaki E., Papadopoulos A.a., Niakas D. Comparing the sensitivity of EQ-5D, SF-6D and 15D utilities to the specific effect of diabetic complications. Eur J Health Econ: HEPAC: Health Econ Prev Care 2012, 13(1):111-120. [accessed 19.09.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/21132558〉.
53. Van der Meer V., van den Hout W.B., Bakker M.J., Rabe K.F., Sterk P.J., Assendelft W.J.J., et al. Cost-effectiveness of Internet-based self-management compared with usual care in asthma. PloS One 2011, 6(11):e27108. [accessed 04.10.13]. 〈http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3214043&tool=pmcentrez&rendertype=Abstract〉.
54. Sobocki P., Ekman M., Agren H., Krakau I., Runeson B., Mårtensson B., et al. Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health: J Int Soc Pharmacoecon Outcomes Res 2007, 10(2):153-160.
55. Fletcher E., Goodwin V.A., Richards S.H., Campbell J.L., Taylor R.S. An exercise intervention to prevent falls in Parkinson's: an economic evaluation. BMC Health Serv Res 2012, 12(1):426. [accessed 04.10.13]. 〈http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3560229&tool=pmcentrez&rendertype=Abstract〉.
56. EQ-5D value sets: inventory, comparative review and user guide 2007, The EuroQol Group's Task Forse on Value Sets, Springer, Netherlands. A. Szende, M. Oppe, N. Devlin (Eds.).
57. Gu N.Y., Bell C., Botteman M.F., Ji X., Carter J.A., van Hout B. Estimating preference-based EQ-5D health state utilities or item responses from neuropathic pain scores. Patient 2012, 5(3):185-197. [accessed 05.03.13]. 〈http://www.ncbi.nlm.nih.gov/pubmed/22765255〉.
58. Dixon S., Retsa P., Odeyemi I., Chambers C., Currie C.J. Evaluation of health-related utility values for pain states characterised by the numeric pain rating scale established using a time trade-off method. Proceedings of the 14th Congress of the European Federation of Neurological Societies (EFNS) 2010, 294. Geneva, 17.